Most recently, the PARAGON‐HF trial, which compared sacubitril/valsartan to valsartan, narrowly missed statistical significance for the primary endpoint of total heart failure hospitalizations and cardiovascular death. 17 However, the data from PARAGON‐HF suggested that patients with LVEF at or below the pre‐specified median of 57% had a greater treatment benefit than those with higher LVEF, and this finding was confirmed when LVEF was assessed continuously.
← all excerpts
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.
1
—
—